Integer Holdings Corporation reported fourth‑quarter 2025 results that surpassed expectations, with revenue of $472.06 million, a 5% year‑over‑year increase, and adjusted earnings per share of $1.76, beating the consensus estimate of $1.70. The beat was driven by strong demand in the Cardio & Vascular segment, which offset a modest decline in the Cardiac Rhythm Management & Neuromodulation business and helped maintain a healthy operating‑income margin of 17.6% for the quarter.
For the full year, Integer delivered $1.854 billion in sales, an 8% increase from 2024, and adjusted earnings per share of $6.40. Adjusted operating income rose 13% to $319 million, reflecting both revenue growth and improved operational leverage. The company’s margin expansion was supported by a higher mix of high‑margin Cardio & Vascular contracts and disciplined cost management.
Segment performance highlighted a robust Cardio & Vascular business, which grew strongly and contributed significantly to the company’s top‑line growth. In contrast, the Cardiac Rhythm Management & Neuromodulation segment experienced a decline, largely due to lower demand from select emerging customers with PMA products. This mix shift helped explain the overall revenue growth while underscoring the company’s focus on its high‑growth core.
Management reiterated its 2026 outlook, maintaining a sales range of $1.83‑$1.85 billion and adjusted EPS guidance of $6.29‑$6.78. The guidance was tightened around the midpoint of the preliminary outlook, reflecting headwinds from new‑product slowdowns and the exit from the Portable Medical line. The company remains confident that underlying growth will offset these challenges.
Integer also announced an accelerated share‑repurchase program, authorizing $50 million of common stock under its existing $200 million program. Payman Khales said the program “reflects the confidence of the Board and management in our strategy, financial position, and ability to generate strong free cash flows.” The buyback signals management’s conviction in the company’s valuation and cash‑flow generation.
Investors reacted positively to the results, citing the earnings beat, strong guidance, and the company’s focus on high‑growth segments. Analysts noted that the company’s ability to maintain margin expansion and its confidence in future growth, despite identified headwinds, contributed to the favorable market reception.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.